Promoter holding
64.27%
MP
Maneesh Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Maneeshpharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Maneeshpharma — 360° Intelligence Report
Generated from MCA filings & public records68/100
Trust Score
Moderate
Maneeshpharma is assessed as Moderate with a Trust Score of 68/100. Maneeshpharma is an active public limited indian non-government company incorporated in 1985, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 28 Jul 2026 from the latest processed filings. Maneesh Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
47/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (18.00 cr) · 35 satisfied (1,045.43 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Icici Bank Limited | 8 | 48.0 cr |
| Pegasus Group Twenty Six Trust - I- Pegasus Assets Reconstruction Private Limited | 3 | 48.0 cr |
| Il & Fs Trust Company Limited | 1 | 48.0 cr |
| Citi Bank N.A. | 4 | 48.0 cr |
| 3I Infotech Trusteeship Services Limited | 5 | 48.0 cr |
| Abn Amro Bank N.V. | 1 | 48.0 cr |
Compliance Score: 47/100 Caution Indicated
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2023 - filings overdue.
- Litigation present in 5 court forum(s).
- Delayed payments to MSME suppliers disclosed (480 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (5)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MANEESH RAMAKANT SAPTE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAKESH KHETAN TUNARAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJIT GOPAL JAMKHANDIKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHETAN SHYAMLAL CHANDWANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRAVIN MOHANDAS HEGDE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAKESH KHETAN TUNARAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RASHMI VINAY SAPTE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINAY RAMAKANT SAPTE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- RAKESH KHETAN TUNARAM has DIN status "Disqualified by RoC u/s 164(2)".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
5
Group entities
6
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Svizera Labs Private Limited | Subsidiary Company | 74.00% |
| Ergos Life Sciences Private Limited | Subsidiary Company | 74.00% |
| Shanbag Storage And Services Private Limited | Subsidiary Company | 74.00% |
| Pharmanova Specialties Private Limited | Subsidiary Company | 74.00% |
| Phaarmasia Limited | Subsidiary Company | 74.00% |
| Svizera Pharma Private Limited | Associate Company | 74.00% |
Key managerial personnel: MANEESH RAMAKANT SAPTE (Whole-time director) · RAKESH KHETAN TUNARAM (CFO) · RAKESH KHETAN TUNARAM (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
Compliance score is weak (47/100).
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 10.73 cr.
5 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence59/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment80/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 18.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view75/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events11 Jul 2023
Last AGM held
Annual general meeting
31 Mar 2023
Director ceased
MANEESH RAMAKANT SAPTE
Director ceased
VINAY RAMAKANT SAPTE
Latest balance sheet
Filed with ROC
23 Dec 2022
Director appointed
CHETAN SHYAMLAL CHANDWANI (Company Secretary)
14 Jul 2022
Charge satisfied
Il & Fs Trust Company Limited
12 Jul 2022
Charge satisfied
Others
Charge satisfied
Alchemist Asset Reconstruction Company Limited
18 Sep 2018
Director ceased
AJIT GOPAL JAMKHANDIKAR
24 Aug 2018
Director appointed
AJIT GOPAL JAMKHANDIKAR (Director)
28 Mar 2018
Director ceased
BHARAT BACHUBAI MERCHANT
04 May 2017
Director ceased
PRAVIN MOHANDAS HEGDE
24 Jan 2017
Charge satisfied
Standard Chartered Bank
19 Jan 2017
Director appointed
PRAVIN MOHANDAS HEGDE (Director)
Director ceased
BHUPINDER NARENDRA GARG
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
8 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 5 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Atotech India Private Limited | U74999HR1996PTC033492 | Haryana, Haryana, India |
| Orica | U24100TS1999FTC181373 | Seri Lingampally, Telangana, India |
| Shivani Detergents | U24243MP1995PTC009534 | Indore, Madhya Pradesh, India |
| Dalmia Dsp Limited | U26942WB1937PLC009086 | Kolkata, West Bengal, India |
| Astral Adhesives | U24295GJ2009PLC058120 | Ahmedabad, Gujarat, India |
| Rachempharma | U24110TG1996PLC022816 | Hyderabad, Telangana, India |
| Meghmani Industries Limited | U29199GJ1993PLC019013 | Ahmedabad, Gujarat, India |
| Bharat Serums & Vaccines | U24230MH1971PLC015134 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Maneeshpharma before audits and certifications: compliance score 47/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Maneeshpharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Maneeshpharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Maneeshpharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (5 case(s) on record), regulatory flags, charge documents trail and director networks for Maneeshpharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Maneeshpharma an active company?
Maneeshpharma has MCA status “Active” with a compliance score of 47/100 (Caution Indicated).
Is Maneeshpharma financially healthy?
Maneeshpharma has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Maneeshpharma?
Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Maneeshpharma?
Promoters hold a majority stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Maneeshpharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 35 earlier charge(s) stand satisfied.
Is Maneeshpharma up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 47/100 (Caution Indicated).
Is it risky to lend to Maneeshpharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
